# A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

> **NCT03947255** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 12 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** brentuximab vedotin

## Key facts

- **NCT ID:** NCT03947255
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-28
- **Primary completion:** 2022-11-06
- **Final completion:** 2022-11-06
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Study stopped early due to low patient accrual.
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947255, "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03947255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*